Gregory J. Gerstner

Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia

Gregory J. Gerstner, Mary Lou Damiano, Abdel Rahman El Tom et al. · Haemophilia · 2009 · 146 citations

Medicine, Orthopedic Surgery, Bone Grafting +15

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee et al. · The Lancet Oncology · 2016 · 134 citations · Full text

Medicine, Oncology, Pharmacology +15

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced<i>EGFR</i>-Mutant Non–Small Cell Lung Cancer

Thomas E. Stinchcombe, Pasi A. Jänne, Xiaofei Wang et al. · JAMA Oncology · 2019 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Martin Reck, Rafał Dziadziuszko, Shunichi Sugawara et al. · Lung Cancer · 2024 · 67 citations

Medicine, Oncology, Pharmacology +10

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Kathleen M. Mullane, Vicki A. Morrison, Luis H. Camacho et al. · The Lancet Infectious Diseases · 2019 · 36 citations

Veterinary Medicine, Immunology, Infectious Diseases +14